Nicholas N. Kallas

Nicholas N. Kallas, Ph.D.

Partner, New York

Nicholas Kallas, Ph.D., has over 30 years of patent law experience, focusing primarily on patent litigation and pre-suit investigations in matters related to pharmaceuticals, chemicals, food and consumer products. Clients recognize Nick’s commitment, knowledge, and professionalism, noting that he “consistently does an excellent job” (Client Report Card 2014). It is no wonder then that clients who have worked with Nick “for 20 years [] would refer him and his firm without hesitation.” (U.S. News – Best Lawyers 2010-11). Nick has significant trial and appellate experience, often serving as lead trial counsel, and brings that experience to bear in how he handles cases.

Specific technologies Nick has worked with include anti-fungal, herpes, breast cancer, osteoporosis, anti-cholesterol, ophthalmic, anti-cholinesterase, and immunosuppressant drugs; microemulsion, enteric coating, and delayed release pharmaceutical formulations; and crystalline drug products.

Case Highlight
Novartis Pharmaceuticals Corporation et al v. Noven Pharmaceuticals Inc.
D. Del. (2015)

Nick secured an affirmance by the Federal Circuit in a Hatch-Waxman litigation concerning Novartis’s Exelon® Transdermal Patches for the treatment of Alzheimer’s Disease. The Federal Circuit agreed that because the stability problem was not known, one of ordinary skill would not have been motivated to fix it.
What Others Say
  • “Nick Kallas consistently does an excellent job for us... I was recently at trial with Fitzpatrick and experienced the best-managed trial I have ever seen” (Client Report Card 2014)
  • “Incredibly knowledgeable [concerning] patent law. His responsiveness and professionalism [are] unparalleled. We have worked with Mr. Kallas and his firm for 20 years and would refer him and his firm without hesitation” (U.S. News – Best Lawyers 2010-2011)
Representative Matters
  • Novartis and LTS Lohmann Therapie-Systeme v. Noven Pharmaceuticals Inc. (rivastigmine Alzheimer’s Disease transdermal patch) (lead counsel) (D. Del.)
  • Novartis and LTS Lohmann Therapie-Systeme v. Watson and Actavis (rivastigmine Alzheimer’s Disease transdermal patch) (lead counsel) (D. Del.)
  • Novartis v. Apotex and Mylan (enteric coated mycophenolate sodium immunosuppressant drug) (lead counsel) (D.N.J.)
  • Novartis v. Mylan (fluvastatin sodium, anti-cholesterol drug) (lead counsel) (D.N.J.)
  • Novartis v. Teva (famciclovir herpes drug) (D.N.J.)
  • Novartis v. Mylan (letrozole breast cancer drug) (lead counsel) (D.N.J.)
  • Novartis v. Watson, Sun and Dr. Reddy’s (rivastigmine tartrate Alzheimer’s Disease drug) (lead counsel) (S.D.N.Y.)
  • Novartis v. Apotex (calcitonin osteoporosis drug) (lead counsel) (S.D.N.Y.)
  • Novartis v. Dr. Reddy’s (terbinafine anti-fungal drug) (lead counsel) (S.D.N.Y.)
  • Parker Laboratories v. Pharmaceutical Innovations (ultrasound transmission gel product) (S.D.N.Y.)
  • Novartis v. Abbott (cyclosporine microemulsion drug) (lead counsel) (D. Del. and Fed. Cir.)
  • Grain Processing v. American Maize-Products (maltodextrin food additives) (co-trial counsel) (N.D. Ill. and Fed. Cir.)
  • Ben Venue v. Novartis (pamidronate disodium drug) (lead counsel) (D.N.J.)
  • Ciba-Geigy v. Crompton & Knowles (red monoazo sulphonic acid dyes) (E.D. Pa.)
  • S.C. Johnson & Son v. Gillette (shaving gel product) (D. Mass. and Fed. Cir.)
  • S.C. Johnson & Son v. Carter-Wallace (shaving gel product) (S.D.N.Y. and Fed. Cir.)
News & Press